[go: up one dir, main page]

MX2018007581A - Dominios variables de inmunoglobulina mejorados. - Google Patents

Dominios variables de inmunoglobulina mejorados.

Info

Publication number
MX2018007581A
MX2018007581A MX2018007581A MX2018007581A MX2018007581A MX 2018007581 A MX2018007581 A MX 2018007581A MX 2018007581 A MX2018007581 A MX 2018007581A MX 2018007581 A MX2018007581 A MX 2018007581A MX 2018007581 A MX2018007581 A MX 2018007581A
Authority
MX
Mexico
Prior art keywords
amino acid
acid residue
variable domains
immunoglobulin variable
improved immunoglobulin
Prior art date
Application number
MX2018007581A
Other languages
English (en)
Inventor
Marie-Ange Buyse
Carlo Boutton
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2018007581A publication Critical patent/MX2018007581A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describe el dominio VH, en el cual: (i) el residuo de aminoácido en la posición 112 es uno de K o Q; y/o (ii) el residuo de aminoácido en la posición en la posición 89 es T; y/o (iii) el residuo de aminoácido en la posición 89 es L y el residuo de aminoácido en la posición 110 es uno de K o Q; y (iv) en cada uno de los casos (i) a (iii), el aminoácido en la posición 11 es de manera preferente V; y en el cual el dominio VH contiene una extensión C-terminal (X)n en el cual n es uno 1 a 10, de manera preferente 1 a 5, tal como 1, 2, 3, 4, o 5 (y de manera preferente 1 o 2, tal como 1); y cada X es un residuo de aminoácido (de manera preferente de origen natural) que se elige independientemente y de manera preferente se elige independientemente del grupo que consiste de alanina (A), glicina (G), valina (V), leucina (L) o isoleucina (I) .
MX2018007581A 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados. MX2018007581A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461994552P 2014-05-16 2014-05-16
US201462014015P 2014-06-18 2014-06-18
US201461014015P 2014-06-18 2014-06-18
US201462040167P 2014-08-21 2014-08-21
US201462047560P 2014-09-08 2014-09-08
US201562133600P 2015-03-16 2015-03-16

Publications (1)

Publication Number Publication Date
MX2018007581A true MX2018007581A (es) 2020-11-12

Family

ID=91193230

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2016014926A MX383560B (es) 2014-05-16 2015-05-13 Dominios variables de inmunoglobulina mejorados.
MX2021007020A MX2021007020A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.
MX2018007581A MX2018007581A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.
MX2023010731A MX2023010731A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2016014926A MX383560B (es) 2014-05-16 2015-05-13 Dominios variables de inmunoglobulina mejorados.
MX2021007020A MX2021007020A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023010731A MX2023010731A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.

Country Status (24)

Country Link
US (10) US12180268B2 (es)
EP (4) EP3248986B1 (es)
JP (6) JP7325928B2 (es)
KR (5) KR20170002645A (es)
CN (3) CN109053885A (es)
AU (6) AU2015261536B2 (es)
BR (2) BR122018009619B1 (es)
CA (2) CA3175002A1 (es)
DK (2) DK3143042T3 (es)
ES (2) ES2912069T3 (es)
HR (2) HRP20200966T1 (es)
HU (2) HUE050007T2 (es)
IL (6) IL295534B2 (es)
LT (2) LT3143042T (es)
MX (4) MX383560B (es)
PH (1) PH12016502282B1 (es)
PL (2) PL3143042T3 (es)
PT (2) PT3143042T (es)
RS (2) RS63085B1 (es)
RU (1) RU2746738C2 (es)
SG (3) SG10201810124PA (es)
SI (2) SI3143042T1 (es)
WO (1) WO2015173325A2 (es)
ZA (5) ZA201607587B (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PH12022550311A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
RS63085B1 (sr) * 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
US10526397B2 (en) 2015-01-21 2020-01-07 Inhibrx, Inc. Non-immunogenic single domain antibodies
NO2768984T3 (es) * 2015-11-12 2018-06-09
EP3374395A1 (en) * 2015-11-12 2018-09-19 Ablynx NV Improved p2x7 receptor binders and polypeptides comprising the same
PT3374392T (pt) 2015-11-13 2022-02-07 Ablynx Nv Domínios variáveis de imunoglobulina que se ligam a albumina sérica melhorados
BR112018009972B1 (pt) * 2015-11-18 2021-08-24 Merck Sharp & Dohme Corp Ligante de ctla4, ligante, recipiente ou dispositivo de injeção, polinucleotídeo, vetor, célula hospedeira, métodos para fabricar o ligante de ctla4 e para prevenir que ctla4 se ligue à cd80 ou cd86 e usos do referido ligante de ctla4
JP7046804B2 (ja) * 2015-11-18 2022-04-04 アブリンクス エン．ヴェー． 改良された血清アルブミン結合剤
WO2017087589A2 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
JP6779997B2 (ja) 2015-11-18 2020-11-04 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ１／ｃｔｌａ４結合性物質
WO2017137579A1 (en) 2016-02-12 2017-08-17 Ablynx Nv Method for the production of immunoglobulin single variable domains
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
RU2765809C2 (ru) 2016-06-23 2022-02-03 Аблинкс Н.В. Усовершенствованные фармакокинетические анализы для одиночных вариабельных доменов иммуноглобулина
KR102665596B1 (ko) 2016-11-16 2024-05-14 아블린쓰 엔.브이. Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
IL310340A (en) * 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
PL3571224T3 (pl) 2017-01-17 2025-01-07 Ablynx Nv Ulepszone środki wiążące albuminę surowicy
CN117285623A (zh) 2017-01-17 2023-12-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
PT3630847T (pt) 2017-06-02 2024-11-21 Merck Patent Gmbh Imunoglobulinas que se ligam a adamts
CN111108126B (zh) 2017-07-19 2024-04-26 非营利性组织佛兰芒综合大学生物技术研究所 血清白蛋白结合剂
CN111315784A (zh) 2017-10-31 2020-06-19 非营利性组织佛兰芒综合大学生物技术研究所 新的抗原结合嵌合蛋白及其方法和用途
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
US20220411495A1 (en) 2019-11-27 2022-12-29 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
PH12022551231A1 (en) 2019-12-06 2023-07-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
WO2021110816A1 (en) 2019-12-06 2021-06-10 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
CN114980974A (zh) 2019-12-09 2022-08-30 艾伯霖克斯公司 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽
CA3165429A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
KR20230012464A (ko) 2020-02-25 2023-01-26 브이아이비 브이지더블유 류신-풍부 반복 키나제 2 알로스테릭 조절제
CN115397868A (zh) 2020-03-30 2022-11-25 埃博灵克斯股份有限公司 用于产生和纯化多价免疫球蛋白单可变域的方法
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
WO2022032040A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb/il2rg synthetic cytokines
US12509522B2 (en) 2020-09-25 2025-12-30 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-13 and OX40L
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
WO2022129637A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
WO2022129560A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
EP4288095A1 (en) 2021-02-05 2023-12-13 Vib Vzw Sarbecovirus binders
WO2022175532A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022206900A1 (zh) * 2021-04-01 2022-10-06 江苏先声药业有限公司 抗人血清白蛋白(hsa)的纳米抗体及其应用
US20240327525A1 (en) 2021-07-30 2024-10-03 Vib Vzw Cation-Independent Mannose-6-Phosphate Receptor Binders For Targeted Protein Degradation
CN118339179A (zh) * 2021-11-29 2024-07-12 江苏恒瑞医药股份有限公司 经修饰的蛋白或多肽
EP4448574A1 (en) 2021-12-17 2024-10-23 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123
EP4463479A1 (en) 2022-01-12 2024-11-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
KR20250008754A (ko) 2022-05-06 2025-01-15 누맙 세러퓨틱스 아게 면역원성이 감소된 항체 가변 도메인 및 항체
CA3249283A1 (en) 2022-05-18 2023-11-23 Vib Vzw BINDERS OF SARBECOVIRUS SPICULE S2 SUBUNITS
JP2025523403A (ja) 2022-06-08 2025-07-23 タイダル・セラビューティクス・インコーポレイテッド イオン化可能なカチオン性脂質及び脂質ナノ粒子、並びにその合成方法及び使用
AR129614A1 (es) 2022-06-14 2024-09-11 Ablynx Nv Dominios variables únicos de inmunoglobulina que se dirigen al receptor de células t
CA3263005A1 (en) 2022-07-27 2024-02-01 Sanofi POLYPEPTIDES BINDING TO A SPECIFIC EPITOPE OF THE NEONATAL FC RECEPTOR
EP4594348A1 (en) 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024137731A2 (en) 2022-12-21 2024-06-27 Genzyme Corporation Anti‑pd‑1×4‑1bb binding proteins
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
EP4648792A2 (en) 2023-01-09 2025-11-19 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
CN121013866A (zh) 2023-02-10 2025-11-25 阿穆尼克斯制药公司 靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法
AU2024221136A1 (en) 2023-02-17 2025-10-02 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
WO2024192065A1 (en) 2023-03-14 2024-09-19 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
AU2024267410A1 (en) 2023-05-08 2026-01-08 Sanofi Glycosylation of immunoglobulin single variable domains
TW202448951A (zh) 2023-05-17 2024-12-16 美商奧迪希治療公司 經修飾之單域抗體
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
AU2024308381A1 (en) 2023-06-29 2025-11-20 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
AR133903A1 (es) 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
AR134267A1 (es) 2023-11-08 2025-12-17 Sanofi Sa Degradador lisosómico basado en cd25 y usos del mismo
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025262150A2 (en) 2024-06-18 2025-12-26 Ablynx Nv Antibody-recruiting molecules
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use
WO2026024863A2 (en) 2024-07-24 2026-01-29 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) * 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5028608A (en) 1989-12-11 1991-07-02 The Trustees Of Princeton University N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives
US5248775A (en) 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ID26964A (id) 1998-02-19 2001-02-22 Xcyte Therapies Inc Komposisi dan metode untuk pengaturan pengaktifan limfosit
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
CA2441903C (en) * 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
EP1412390A2 (en) 2001-07-26 2004-04-28 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
KR101103218B1 (ko) 2002-11-08 2012-01-05 아블린쓰 엔.브이. 종양 괴사 인자-알파에 대한 단일 도메인 항체 및 그 용도
EP2258392A1 (en) 2002-11-08 2010-12-08 Ablynx N.V. Method of administering therapeutic polypeptides
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
AU2005250216B2 (en) 2004-06-01 2009-12-10 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
EP1863847A2 (en) 2004-12-02 2007-12-12 Domantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
CN101128487B (zh) 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
MX363423B (es) * 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
HUE039846T2 (hu) 2005-05-20 2019-02-28 Ablynx Nv Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére
WO2006129843A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
BRPI0619224A2 (pt) 2005-12-01 2017-06-20 Domantis Ltd monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
JP2009519011A (ja) 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
EP2102241A2 (en) 2006-12-15 2009-09-23 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
WO2012130874A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Bispecific anti-cxcr7 immunoglobulin single variable domains
CN104231082B (zh) 2007-05-24 2018-12-21 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
RU2540150C2 (ru) 2007-06-25 2015-02-10 Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк Способы модификации антител и модифицированные антитела с улучшенными функциональными свойствами
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EP2259802A1 (en) 2008-03-31 2010-12-15 Glaxo Group Limited Drug fusions and conjugates
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
WO2009138494A2 (en) 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
CN102099378B (zh) 2008-05-16 2016-01-20 埃博灵克斯股份有限公司 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110200525A1 (en) 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
EA021146B1 (ru) 2009-03-27 2015-04-30 Глаксо Груп Лимитед Продукты слияния и конъюгаты лекарственных средств
EP3828201A1 (en) 2009-04-30 2021-06-02 Ablynx N.V. Method for the production of domain antibodies
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2010142534A1 (en) 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
AU2010251966A1 (en) 2009-05-28 2011-12-22 Glaxo Group Limited Combination of a TNF-alpha antagonist and a VEGF antagonist for use in the treatment or prevention of diseases of the eye.
EP2451839B1 (en) 2009-07-10 2020-04-22 Ablynx N.V. Method for the production of variable domains
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
EP2486056A1 (en) 2009-10-09 2012-08-15 Ablynx N.V. Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
EP3309176B1 (en) * 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
KR101721187B1 (ko) * 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
CN102971341A (zh) 2010-04-30 2013-03-13 埃博灵克斯股份有限公司 针对异二聚体细胞因子IL-23的p19亚基的纳米抗体的氨基酸序列
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
WO2011161266A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
JP2013145769A (ja) 2010-08-04 2013-07-25 Kri Inc 異方性希土類ボンド磁石とその製造方法
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US20130310281A1 (en) 2011-02-02 2013-11-21 Glaxo Group Limited Novel antigen binding proteins
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AU2012273928A1 (en) 2011-06-23 2014-02-06 Ablynx Nv Immunoglobulin single variable domains directed against IgE
PH12022550311A1 (en) * 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IN2014CN00414A (es) * 2011-06-23 2015-04-03 Ablynx Nv
US20130019175A1 (en) 2011-07-14 2013-01-17 Microsoft Corporation Submenus for context based menu system
KR102143506B1 (ko) 2011-08-17 2020-08-12 글락소 그룹 리미티드 변형된 단백질 및 펩티드
EP2747783B1 (en) 2011-09-30 2017-06-14 Ablynx N.V. Biological materials related to c-met
KR20140082824A (ko) 2011-10-17 2014-07-02 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
SMT202100628T1 (it) 2012-01-31 2022-01-10 Regeneron Pharma Anticorpi anti-asic1 e usi degli stessi
US9908935B2 (en) 2012-06-01 2018-03-06 Ablynx N.V. P2X7 receptor antagonists and agonists
TW201843172A (zh) * 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
CN104781277A (zh) * 2012-09-13 2015-07-15 诺华股份有限公司 具有末端修饰的抗原结合分子
US9667316B2 (en) 2013-05-17 2017-05-30 The Boeing Company Aircraft data transmission using phase separation
RS63085B1 (sr) 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
RU2018119732A (ru) 2015-10-30 2019-12-03 Аблинкс Нв Полипептиды против il-23
EP3374395A1 (en) 2015-11-12 2018-09-19 Ablynx NV Improved p2x7 receptor binders and polypeptides comprising the same
NO2768984T3 (es) 2015-11-12 2018-06-09
PT3374392T (pt) 2015-11-13 2022-02-07 Ablynx Nv Domínios variáveis de imunoglobulina que se ligam a albumina sérica melhorados
WO2017087589A2 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
JP6779997B2 (ja) 2015-11-18 2020-11-04 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ１／ｃｔｌａ４結合性物質
BR112018009972B1 (pt) 2015-11-18 2021-08-24 Merck Sharp & Dohme Corp Ligante de ctla4, ligante, recipiente ou dispositivo de injeção, polinucleotídeo, vetor, célula hospedeira, métodos para fabricar o ligante de ctla4 e para prevenir que ctla4 se ligue à cd80 ou cd86 e usos do referido ligante de ctla4
JP7046804B2 (ja) 2015-11-18 2022-04-04 アブリンクス エン．ヴェー． 改良された血清アルブミン結合剤
PL3571224T3 (pl) 2017-01-17 2025-01-07 Ablynx Nv Ulepszone środki wiążące albuminę surowicy
WO2021110816A1 (en) 2019-12-06 2021-06-10 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α

Also Published As

Publication number Publication date
IL299282B1 (en) 2024-05-01
US12180268B2 (en) 2024-12-31
ZA202004757B (en) 2022-08-31
KR20230054503A (ko) 2023-04-24
KR102827683B1 (ko) 2025-06-30
BR122018009619B1 (pt) 2024-01-02
EP3248986A2 (en) 2017-11-29
AU2015261536A1 (en) 2016-11-17
MX2016014926A (es) 2017-05-09
IL248636B2 (en) 2023-04-01
JP7098439B2 (ja) 2022-07-11
IL281755B2 (en) 2023-05-01
US11708404B2 (en) 2023-07-25
IL259972A (en) 2018-07-31
RU2018120744A3 (es) 2022-01-28
PH12016502282A1 (en) 2017-02-13
EP3143042A2 (en) 2017-03-22
IL281755A (en) 2021-05-31
PT3248986T (pt) 2022-04-05
KR20230145503A (ko) 2023-10-17
IL295534B2 (en) 2025-03-01
WO2015173325A3 (en) 2016-02-18
JP2017518072A (ja) 2017-07-06
US20210269514A1 (en) 2021-09-02
CA2948076A1 (en) 2015-11-19
JP2024069377A (ja) 2024-05-21
HUE050007T2 (hu) 2020-11-30
HUE058008T2 (hu) 2022-06-28
IL259972B (en) 2021-04-29
US20220332806A1 (en) 2022-10-20
IL295534B1 (en) 2024-11-01
SG11201609162SA (en) 2016-12-29
US11319364B2 (en) 2022-05-03
JP2021006563A (ja) 2021-01-21
EP3702369A1 (en) 2020-09-02
RU2016149463A (ru) 2018-06-19
US11312765B2 (en) 2022-04-26
DK3248986T3 (da) 2022-04-04
IL248636A0 (en) 2017-01-31
US20170121399A1 (en) 2017-05-04
CN106661100A (zh) 2017-05-10
US20210269515A1 (en) 2021-09-02
RS63085B1 (sr) 2022-04-29
AU2018204226A1 (en) 2018-07-05
US20210087261A1 (en) 2021-03-25
RU2018120744A (ru) 2018-11-15
RS60717B1 (sr) 2020-09-30
EP3248986B1 (en) 2022-01-26
CA3175002A1 (en) 2015-11-19
JP2024041939A (ja) 2024-03-27
IL299282B2 (en) 2024-09-01
IL299282A (en) 2023-02-01
IL295534A (en) 2022-10-01
AU2020202570A1 (en) 2020-05-07
US20200231662A1 (en) 2020-07-23
PH12016502282B1 (en) 2024-05-22
KR102769509B1 (ko) 2025-02-17
PT3143042T (pt) 2020-09-01
MX2023010731A (es) 2023-09-20
KR20230053002A (ko) 2023-04-20
IL311293B2 (en) 2025-07-01
SG10201810124PA (en) 2018-12-28
ZA202004759B (en) 2022-08-31
WO2015173325A8 (en) 2016-12-29
RU2021107470A (ru) 2021-05-17
JP7325928B2 (ja) 2023-08-15
KR20170002645A (ko) 2017-01-06
BR112016026773A2 (pt) 2017-12-12
SG10201805288QA (en) 2018-07-30
ZA202100742B (en) 2022-09-28
ES2815572T3 (es) 2021-03-30
EP3143042B1 (en) 2020-06-10
AU2022279374B2 (en) 2026-01-15
SI3248986T1 (sl) 2022-04-29
JP7454525B2 (ja) 2024-03-22
HRP20200966T1 (hr) 2020-10-16
ZA201607587B (en) 2022-05-25
AU2020202855A1 (en) 2020-05-21
AU2015261536B2 (en) 2020-05-07
AU2022279373A1 (en) 2023-01-19
US20220332807A1 (en) 2022-10-20
SI3143042T1 (sl) 2020-08-31
MX383560B (es) 2025-03-14
HRP20220400T1 (hr) 2022-05-27
JP2018162297A (ja) 2018-10-18
MX2021007020A (es) 2021-08-05
JP2021130681A (ja) 2021-09-09
IL311293A (en) 2024-05-01
PL3143042T3 (pl) 2020-11-16
EP3693386A1 (en) 2020-08-12
CN109053885A (zh) 2018-12-21
IL281755B1 (en) 2023-01-01
DK3143042T3 (da) 2020-08-31
AU2022279374A1 (en) 2023-01-19
AU2020202855B2 (en) 2022-12-08
LT3248986T (lt) 2022-03-25
US20220119512A1 (en) 2022-04-21
US20210261653A1 (en) 2021-08-26
US11485778B2 (en) 2022-11-01
US20220135657A9 (en) 2022-05-05
ZA202004758B (en) 2022-08-31
ES2912069T3 (es) 2022-05-24
EP3248986A3 (en) 2017-12-20
LT3143042T (lt) 2020-07-27
PL3248986T3 (pl) 2022-05-16
AU2020202570B2 (en) 2022-12-08
WO2015173325A2 (en) 2015-11-19
IL248636B (en) 2022-12-01
IL311293B1 (en) 2025-03-01
KR20180091115A (ko) 2018-08-14
RU2746738C2 (ru) 2021-04-20
RU2016149463A3 (es) 2018-07-04
CN113717280A (zh) 2021-11-30
JP7471987B2 (ja) 2024-04-22
US20220251183A1 (en) 2022-08-11
US11220539B2 (en) 2022-01-11
US11485777B2 (en) 2022-11-01
NZ726448A (en) 2023-02-24
US11312764B2 (en) 2022-04-26

Similar Documents

Publication Publication Date Title
MX2021007020A (es) Dominios variables de inmunoglobulina mejorados.
MX378451B (es) Variantes de regiòn fc con uniòn del receptor fc neonatal (fcrn) modificado y mètodos de uso.
EA201790465A1 (ru) Антитела, композиции и применение
NZ780183A (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG10201909716RA (en) Modified j-chain
MX2020003260A (es) Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
NZ749292A (en) Compositions and methods related to engineered fc constructs
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
MY182177A (en) Method for masking bitterness of composition containing collagen peptide
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
MX2018014490A (es) Peptido antimicrobiano modificado derivado de un dominio rico en arginina.
IL270917A (en) Recombinant ROBO2 proteins, preparations, methods and their use
WO2014152831A3 (en) Targeting peptides and uses thereof
WO2015153949A3 (en) Compositions and methods for identifying ehrlichia species
MX2016010431A (es) Composiciones para la prevencion y/o el tratamiento de patologias relacionadas con alfa-glucosidasa.
WO2014166500A3 (en) Peptides having immune suppresive domains for transfection
PH12017550079A1 (en) Composition for improving memory, learning ability and cognition
NZ763845A (en) Improved immunoglobulin variable domains
SI3171885T1 (sl) Peptidni hidrolizat polžev, peptidne frakcije, postopek izdelave, uporaba in sestavki za zaviranje angiotenzinske konvertaze